Abstract

Here, we demonstrate the therapeutic effects of transcranial photobiomodulation (tPBM, 1267nm, 32J/cm2, a 9-day course) in mice with the injected model of Alzheimer's disease (AD) associated with accumulation of beta-amyloid (Aβ) in the brain resulting in neurocognitive deficit vs. the control group (CG) (the neurological severity score (NNS), AD 3.67±0.58 vs. CG 1.00±0.26%, p<0.05) and mild cerebral hypoxia (AD 72±6% vs. CG 97±2%, p<0.001). The course of tPBM improved neurocognitive status of mice with AD (NNS, AD 2.03±0.14 vs. CG 1.00±0.26, vs. 2.03±0.14, p<0.05) due to stimulation of clearance of Aβ from the brain via the meningeal lymphatic vessels (the immunohistochemical and confocal data) and an increase in blood oxygen saturation of the brain tissues (the pulse oximetry data) till 85±2%, p<0.05. These results open breakthrough strategies for non-pharmacological therapy of AD and clearly demonstrate that tPBM might be a promising therapeutic target for preventing or delaying AD based on stimulation of oxygenation of the brain tissues and activation of clearance of toxic molecules via the cerebral lymphatics.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call